Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease
一项针对轻度认知障碍和阿尔茨海默病引起的轻度至中度痴呆的tau蛋白聚集抑制剂甲磺酸氢甲基硫氨酸的3期临床试验的临床、影像学和血液生物标志物结果
期刊:Jpad-Journal of Prevention of Alzheimers Disease
影响因子:7.8
doi:10.1016/j.tjpad.2026.100480
Wischik, Claude M; Stefanacci, Richard; Bentham, Peter; Gauthier, Serge; Zetterberg, Henrik; Wilcock, Gordon K; Froelich, Lutz; Burns, Alistair; MacSweeney, Emer; Ballard, Clive; Yu, Jin-Tai; Choon, Tay Siew; Asvatourian, Vahe; Muehlemann, Natalia; Priel, Jan; Kook, Karin; Sullivan, Tenecia; Downie, Diane; Miller, Sonya; Pringle, Carol; Storey, John M D; Baddeley, Tom; Harrington, Charles R; Penny, Lewis K; Arastoo, Mohammad; Staff, Roger; Sandu, Anca-Larisa; Shiells, Helen; Lo, Serena; Nazlee, Nafeesa; Evans, Emily; Hull, Claire; Schelter, Bjoern O
